Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian P O'Sullivan

Showing results (31-40 of 31) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 31 results.
The Lancet. Respiratory Medicine|November 7, 2022
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsNicole Mayer-Hamblett, Felix Ratjen, Renee Russell, et al.
Pageof 4

Showing results (31-40 of 31) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 31 results.
The Lancet. Respiratory Medicine|November 7, 2022
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsNicole Mayer-Hamblett, Felix Ratjen, Renee Russell, et al.
Pageof 4